Stockscreener 앱 받기
16.29
0.67%
-0.11
전일 마감가:
$16.40
열려 있는:
$16.35
하루 거래량:
99,916
Relative Volume:
1.06
시가총액:
$336.92M
수익:
$306.91M
순이익/손실:
$-59.11M
주가수익비율:
-108.60
EPS:
-0.15
순현금흐름:
$6.35M
1주 성능:
-17.39%
1개월 성능:
-0.55%
6개월 성능:
+51.39%
1년 성능:
+40.50%
1일 변동 폭
$16.16
$17.00
1주일 범위
$16.16
$20.57
52주 변동 폭
$7.08
$20.90
Amarin Corp Adr Stock (AMRN) Company Profile
명칭
Amarin Corp Adr
전화
353 1 6699 020
주소
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
AMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRN
Amarin Corp Adr
|
16.29 | 341.00M | 306.91M | -59.11M | 6.35M | -0.15 |
|
LLY
Lilly Eli Co
|
862.86 | 757.06B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
188.87 | 455.48B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
218.04 | 403.13B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
123.79 | 235.26B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
85.98 | 215.51B | 63.43B | 16.42B | 14.72B | 6.4861 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-10-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-05-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-05 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-05-05 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-04 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-05-12 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-05-05 | 개시 | Northland Capital | Outperform |
| 2020-03-31 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-31 | 업그레이드 | Oppenheimer | Underperform → Perform |
| 2020-03-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-02 | 개시 | Cowen | Outperform |
| 2020-02-18 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-01-06 | 개시 | JP Morgan | Neutral |
| 2019-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-11-20 | 개시 | Oppenheimer | Underperform |
| 2019-11-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-11-15 | 재확인 | SVB Leerink | Outperform |
| 2019-10-31 | 개시 | Aegis Capital | Buy |
| 2019-10-15 | 개시 | Goldman | Neutral |
| 2019-08-14 | 개시 | SVB Leerink | Outperform |
| 2019-07-09 | 재확인 | Jefferies | Buy |
| 2019-06-17 | 개시 | ROTH Capital | Buy |
| 2019-03-22 | 개시 | Stifel | Buy |
모두보기
Amarin Corp Adr 주식(AMRN)의 최신 뉴스
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program - ADVFN
Cash from operating activities of Amarin Corporation Plc Sponsored ADR – SWB:EH3 - TradingView
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress - GlobeNewswire Inc.
Amarin Corporation plc (NASDAQ:AMRN) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - Sahm
Amarin Corporation plc Announces $17.8 Million Registered Direct Offering of American Depositary Shares - ADVFN
Earnings call transcript: Amarin Q2 2025 sees revenue beat, stock stable - Investing.com
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Amarin Gears Up To Report Q2 Earnings: Here's What To Expect - Barchart.com
VKTX Stock Down On Wider-Than-Expected Loss In Q2, Nil Sales - Barchart.com
Zacks.com featured highlights include Mama's Creations, Bassett Furniture Industries and Amarin - Barchart.com
3 Strong Buy Breakout Stocks for Explosive Returns - The Globe and Mail
KRYS Begins Dosing With Gene Therapy In Rare Eye Disease, Stock Up - Barchart.com
RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com
PROK Surges More Than 500% On Upbeat Data From Kidney Cell Therapy Study - Barchart.com
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Yahoo Finance
Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA - Sahm
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
KURA Stock Rises More Than 15% This Past Week: Here's Why - Barchart.com
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
SpringWorks Gets CHMP Nod For Mirdametinib In Rare Disease - Barchart.com
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y - Barchart.com
Amarin earnings beat by $0.04, revenue topped estimates - Investing.com
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Barchart.com
Amarin Corp PLC Share Price ADR Each Rep 20 Ord Spon - Hargreaves Lansdown
Amarin announces ADS ratio change to meet Nasdaq requirements - Investing.com
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Amarin announces board member departure ahead of annual meeting - Investing.com
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
Amarin urged to review strategy by major shareholders - Investing.com
The Market Doesn't Like What It Sees From Amarin Corporation plc's (NASDAQ:AMRN) Revenues Yet As Shares Tumble 26% - Sahm
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Plans Major ADR Restructuring: What This 1:20 Ratio Change Means for Investors - Stock Titan
Amarin stock plunges to 52-week low of $0.46 amid challenges - Investing.com
Amarin granted extension to meet Nasdaq listing standards - Investing.com
Top 3 Health Care Stocks You'll Regret Missing In Q4Amarin Corp (NASDAQ:AMRN) - Benzinga
Amarin to present new cardiovascular research at ESC Congress - Investing.com
China approves VASCEPA to reduce cardiovascular risk - Investing.com
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Investing.com UK
Amarin's VAZKEPA gains reimbursement approval in Greece - Investing.com
Amarin secures new patent for heart drug VAZKEPA in Europe - Investing.com
Free float of Amarin Corporation Plc Sponsored ADR – NASDAQ:AMRN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Sarissa Capital Calls for Amarin Special Meeting to Vote on Its Nominees - 24/7 Wall St.
股神出手｜畢菲特首度買進台積電ADR 涉逾41.2億美元 4家避險基金均增持台積電 - Yahoo 財經
Amarin CorpADR (AMRN) News, Articles, Events & Latest Updates - Stocktwits
Validea Kenneth Fisher Strategy Daily Upgrade Report9/24/2022 - Nasdaq
AMRN Forecast — Price Target — Prediction for 2026 - TradingView
Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics - Nasdaq
HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan - The Globe and Mail
The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs - Yahoo Finance
Amarin Corp Adr (AMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.71%
1.48%
자본화:
|
볼륨(24시간):